Investing.com --Evercore ISI upgraded Hyatt Hotels (NYSE:H) to "outperform" from "in-line" citing an attractive entry point following the stock’s post-earnings selloff and underperformance ...
It has been about a month since the last earnings report for Evercore (EVR). Shares have lost about 26.3% in that time frame, underperforming the S&P 500. Will the recent negative trend continue ...
In a report released on February 28, Kirk Materne from Evercore ISI maintained a Buy rating on AvePoint (AVPT – Research Report), with a price target of $18.00. The company’s shares closed ...
Evercore ISI analyst Amit Daryanani maintained a Hold rating on Ingram Micro Holding Corporation (INGM – Research Report) yesterday and set a price target of $26.00. The company’s shares ...
Fintel reports that on February 14, 2025, Evercore ISI Group upgraded their outlook for CRISPR Therapeutics (BRSE:1CG) from In-Line to Outperform. There are 577 funds or institutions reporting ...
Fortrea stock opened at $10.96 on Tuesday. The stock has a market cap of $983.11 million, a P/E ratio of -3.20, a PEG ratio of 1.78 and a beta of 1.34. The company has a debt-to-equity ratio of 0. ...
Also, Evercore ISI upgrades shares to Outperform from In-Line with a $14 price target, raised from $12, believing the market underappreciates the Hawaii Supreme Court decision that lowers the ...
CRSP stock opened at $49.72 on Friday. The business’s 50-day moving average price is $41.89 and its 200-day moving average price is $46.10. The stock has a market cap of $4.24 billion, a P/E ...
Fintel reports that on March 5, 2025, Evercore ISI Group upgraded their outlook for Hyatt Hotels (NYSE:H) from In-Line to Outperform. As of March 4, 2025, the average one-year price target for ...
Hosted on MSN29d
Evercore ISI Group Upgrades CRISPR Therapeutics (CRSP)Fintel reports that on February 14, 2025, Evercore ISI Group upgraded their outlook for CRISPR Therapeutics (NasdaqGM:CRSP) from In-Line to Outperform. Analyst Price Forecast Suggests 90.46% ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results